Clinical significance of expression levels of serum ADRA1A in hysterocarcinoma patients

Peng,Lin; Peng,Wei; Hu,Peng; Zhang,Hui-Feng

doi:10.3892/ol.2018.8465

Clinical significance of expression levels of serum ADRA1A in hysterocarcinoma patients

Authors:
- Lin Peng
- Wei Peng
- Peng Hu
- Hui-Feng Zhang
View Affiliations

Affiliations: Department of Gynecologic Oncology, Hubei Cancer Hospital, Wuhan, Hubei 430070, P.R. China, Department of Radiology, Hubei Cancer Hospital, Wuhan, Hubei 430079, P.R. China
Published online on: April 11, 2018 https://doi.org/10.3892/ol.2018.8465
Pages: 9162-9166
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The clinical significance of the expression level of serum adrenergic receptor α1 (ADRA1A) in hysterocarcinoma patients was determined. Peripheral serum samples were collected at the Hubei Cancer Hospital from 455 patients affected by hysterocarcinoma and 380 healthy adults, who served as the normal control group. We determined the expression levels of ADRA1A by ELISA and analyzed its correlation to clinical features and prognosis of the patients. Compared with the normal control group, the expression of ADRA1A in the average peripheral serum level of hysterocarcinoma patients was clearly increased (P<0.05). In addition, the expression level of ADRA1A was positively correlated with the FIGO staging for hysterocarcinoma (r=0.312, P=0.014). Furthermore, the expression levels of serum ADRA1A in patients with metastasis were significantly increased compared to the levels of hysterocarcinoma patients without metastasis (P<0.05). Our analyses also showed that the expression levels of serum ADRA1A in hysterocarcinoma patients did not correlate with patient factors such as age, tumor invasive depth, tumor size or tumor differentiation degree (P>0.05). The Kaplan-Meier survival analysis indicated that the median survival time (37.1 months) of patients with a high expression of serum ADRA1A was lower than that of patients with a low expression of serum ADRA1A (68 months) (P<0.05). The three- and five-year survival rates of patients expressing low serum ADRA1A were, respectively, 74.00 and 62.00%; and the three- and five-year survival rates of patients expressing high levels of serum ADRA1A were 52.00 and 32.00%, respectively, with all the differences being statistically significant (P<0.05). ADRA1A was highly expressed in the peripheral serum in patients with hysterocarcinoma and the expression of ADRA1A was associated with FIGO staging and lymph node metastasis status. The expression of serum ADRA1A can be used to assess the survival rate and may be involved in the pathogenesis and metastasis progression of hysterocarcinoma.

View Figures

View References

1	Fei R, Chen J and Du P: The expression of miR-574-5p in cervical cancer tissue and its downregulation influence on cervical cancer SiHa cell. Basic Clin Med. 35:458–462. 2015.
2	Berridge MJ, Bootman MD and Roderick HL: Calcium signalling: Dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 4:517–529. 2003. View Article : Google Scholar : PubMed/NCBI
3	Zong S, Wang X, Yang Y, Wu W, Li H, Ma Y, Lin W, Sun T, Huang Y, Xie Z, et al: The use of cisplatin-loaded mucoadhesive nanofibers for local chemotherapy of cervical cancers in mice. Eur J Pharm Biopharm. 93:127–135. 2015. View Article : Google Scholar : PubMed/NCBI
4	Shazly SA, Murad MH, Dowdy SC, Gostout BS and Famuyide AO: Robotic radical hysterectomy in early stage cervical cancer: A systematicreview and meta-analysis. Gynecol Oncol. 138:457–471. 2015.https://doi.org/10.1016/j.ygyno.2015.06.009 View Article : Google Scholar : PubMed/NCBI
5	Belhadj H, Rasanathan JJ, Denny L and Broutet N: Sexual and reproductive health and HIV services: Integrating HIV/AIDS and cervical cancer prevention and control. Int J Gynaecol Obstet. 121 Suppl 1:S29–S34. 2013. View Article : Google Scholar : PubMed/NCBI
6	Mabeya H, Khozaim K, Liu T, Orango O, Chumba D, Pisharodi L, Carter J and Cu-Uvin S: Comparison of conventional cervical cytology versus visual inspection with acetic acid among human immunodeficiency virus-infected women in Western Kenya. J Low Genit Tract Dis. 16:92–97. 2012.7. View Article : Google Scholar : PubMed/NCBI
7	Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, Mudenda V, Hicks ML, Vermund SH, Stringer JS and Parham GP: Implementation of ‘see-and-treat’ cervical cancer prevention services linked to HIV care in Zambia. AIDS. 23:N1–N5. 2009. View Article : Google Scholar : PubMed/NCBI
8	Byrd TL, Peterson SK, Chavez R and Heckert A: Cervical cancer screening beliefs among young Hispanic women. Prev Med. 38:192–197. 2004. View Article : Google Scholar : PubMed/NCBI
9	Loo SK, Fisher SE, Francks C, Ogdie MN, MacPhie IL, Yang M, McCracken JT, McGough JJ, Nelson SF, Monaco AP, et al: Genome-wide scan of reading ability in affected sibling pairs with attention-deficit/hyperactivity disorder: Unique and shared genetic effects. Mol Psychiatry. 9:485–493. 2004. View Article : Google Scholar : PubMed/NCBI
10	Cole SW and Sood AK: Molecular pathways: Beta-adrenergic signaling in cancer. Clin Cancer Res. 18:1201–1206. 2012. View Article : Google Scholar : PubMed/NCBI
11	Fitzgerald PJ: Beta blockers, norepinephrine, and cancer: An epidemiological viewpoint. Clin Epidemiol. 4:151–156. 2012. View Article : Google Scholar : PubMed/NCBI
12	Fitzgerald PJ: Is norepinephrine an etiological factor in some types of cancer? Int J Cancer. 124:257–263. 2009. View Article : Google Scholar : PubMed/NCBI
13	Freitas SR, Pereira AC, Floriano MS, Mill JG and Krieger JE: Association of alpha1a-adrenergic receptor polymorphism and blood pressure phenotypes in the Brazilian population. BMC Cardiovasc Disord. 8:402008. View Article : Google Scholar : PubMed/NCBI
14	Liu YR, Loh EW, Lan TH, Chen SF, Yu YH, Chang YH, Huang CJ, Hu TM, Lin KM, Yao YT, et al: ADRA1A gene is associated with BMI in chronic schizophrenia patients exposed to antipsychotics. Pharmacogenomics J. 10:30–39. 2010. View Article : Google Scholar : PubMed/NCBI
15	Higgins JR and Gosling JA: Studies on the structure and intrinsic innervation of the normal human prostate. Prostate Suppl. 2(S2): 5–16. 1989. View Article : Google Scholar : PubMed/NCBI
16	Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M and Marshall I: Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol. 74:585–589. 1994. View Article : Google Scholar : PubMed/NCBI
17	He L and Huang C: MiR-19b and miR-16 cooperatively signaling target the regulator ADRA1A in Hypertensive heart disease. Biomed Pharmacother. 91:1178–1183. 2017. View Article : Google Scholar : PubMed/NCBI
18	Katsogiannou M, El Boustany C, Gackiere F, Delcourt P, Athias A, Mariot P, Dewailly E, Jouy N, Lamaze C, Bidaux G, et al: Caveolae contribute to the apoptosis resistance induced by the α(1A)-adrenoceptor in androgen-independent prostate cancer cells. PLoS One. 4:e70682009. View Article : Google Scholar : PubMed/NCBI
19	Li J, Yang XM, Wang YH, Feng MX, Liu XJ, Zhang YL, Huang S, Wu Z, Xue F, Qin WX, et al: Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. J Hepatol. 60:1225–1234. 2014. View Article : Google Scholar : PubMed/NCBI
20	Baalbergen A, Ewing-Graham PC, Hop WC, Struijk P and Helmerhorst TJ: Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol. 92:262–267. 2004. View Article : Google Scholar : PubMed/NCBI
21	Taheri-Kadkhoda Z, Pettersson N, Björk-Eriksson T and Johansson KA: Superiority of intensity-modulated radiotherapy over three-dimensional conformal radiotherapy combined with brachytherapy in nasopharyngeal carcinoma: a planning study. Br J Radiol. 81:397–405. 2008. View Article : Google Scholar : PubMed/NCBI
22	Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R and Terakawa N: Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol. 26:464–467. 2000. View Article : Google Scholar : PubMed/NCBI
23	Douine M, Roue T, Fior A, Adenis A, Thomas N and Nacher M: Survival of patients with invasive cervical cancer in French Guiana, 2003–2008. Int J Gynaecol Obstet. 125:166–167. 2014. View Article : Google Scholar : PubMed/NCBI